ProBioGen AG, a Berlin-based contract development and manufacturing organization (CDMO) for developing and manufacturing complex therapeutic glycoproteins, has appointed Dr. Lutz Hilbrich as chief executive officer, effective June 1, 2020.   Hilbrich was recently vice president, head of biosimilars platform, Sanofi China. He is a seasoned leader with strong international experience, particularly in the U.S., China and Europe. He spent his last 20 years with two major pharmaceutical companies, Bo...